GSK Pays $321M For Swiss Vaccine Developer Okairos
Okairos is a Basel-based drugmaker developing techniques to deliver genetic material to cells to stimulate immune responses that treat cancer and infectious diseases. The acquisition gives GSK a new platform of potential vaccines to complement its existing vaccine department.
GSK now assumes full ownership of Okairos and its early-stage vaccine treatments that could fight a variety...
To view the full article, register now.